Reported Friday, Cellectar Biosciences Announces Plan To Restate Financials, Delays 10-Q Filing, And Receives Nasdaq Non-Compliance Notification
Reported Friday, Cellectar Biosciences Announces Plan To Restate Financials, Delays 10-Q Filing, And Receives Nasdaq Non-Compliance Notification
Cellectar Biosciences在週五宣佈了重新編制財務報表的計劃，延遲了10-Q的提交，並收到了納斯達克的違規通知。
- The Notice indicated that the Company is not in compliance with the periodic financial report filing requirement set forth in Nasdaq Listing Rule 5250(c)(1) as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the "Second Quarter 10-Q"), by the applicable due date.
- The delay in filing the Second Quarter 10-Q is a result of the Company's need to restate certain previously filed financial statements.
- 此通知指出，由於未按規定的納斯達克上市規則5250(c)(1)提交定期財務報告的要求，公司未能按照規定的截止日期前提交截至2024年6月30日的季度報告第10-Q（"第二季度10-Q"）。
- 延遲提交第二季度10-Q的原因是因爲公司需要對先前提交的某些財務報表進行重述。
資訊熱榜
更新時間